Staff Profile

Previously: 

• Background in biological sciences and statistics.  Twenty years in pharmaceutical R&D: Including work for Astra Zeneca, Eli Lilly, GSK, Roche and Sanofi-Aventis.  Data Management and Statistics; Project Planning; R&D Management. Followed by three years in the NHS working in Clinical Data Management and Clinical Research Coordination.

Research interests:

• Scientific behaviours and R&D decision modelling – see Torching The Haystack, The Development Speed Paradox, Rational Optimism in Drug Discovery, The Will To Kill and R&D Productivity Rides Again.

Publications:

• Statistical modelling in a number of fields; formerly Editor of the journal Pharmaceutical Statistics; contributor to popular magazines such as New Scientist and the Economist. 

Professional:

• NIHR Newcastle Biomedical Research Centre, Newcastle University.
• Statistical reviewer for the journals Pharmaceutical Statistics, Statistics in Medicine, Nature Reviews Drug Discovery, Drug Discovery Today, Trials and others. 
• NIHR and MRC statistical reviewer. 
• Chartered Statistician 1992. Formerly member of American Statistical Association and Statisticians in the Pharmaceutical Industry. UK Representative to the European Federation of Statisticians in the Pharmaceutical Industry and Fellow of the Royal Statistical Society. 

 Current research interests include:  

• Stochastic models of drug development
• Models of clinical decision making
• Clinical phenotyping
• R&D management strategies
• Scientific decision making.
  

 Statistical consulting support to postgraduate researchers:

• Mathematical modelling, experimental design and statistics at Newcastle University. Supervision of research projects.
• Postgraduate training and continuing professional development for scientists and statisticians in the pharmaceutical industry. 

• Baker KF, Hanrath AT, Schim van der Loeff I, Tee SA, Capstick R, Marchitelli G, Li A, Barr A, Eid A, Ahmed S, Bajwa D, Mohammed O, Alderson N, Lendrem C, Lendrem DW, COVID Control Group THE, COVID Clinical Group THE, Pareja-Cebrian L, Welch A, Field J, Payne BAI, Taha Y, Price DA, Gibbins C, Schmid ML, Hunter E, Duncan CJA. COVID-19 Management in a UK NHS Foundation Trust with a High Consequence Infectious Diseases Centre: A Retrospective Analysis. Medical Sciences 2021, 9(1), 6.
• Mehta P, Sanchez E, Moraitis E, Longley N, Lendrem DW, Giles IP, Chambers RC, Ciurtin C, Isaacs JD. Influenza vaccination and interruption of methotrexate in adult patients in the COVID-19 era: an ongoing dilemma. The Lancet Rheumatology 2021, 3(1), e9-e10.
• Banks AM, Whitfield CJ, Brown SR, Fulton DA, Goodchild SA, Grant C, Love J, Lendrem D, Fieldsend JE, Howard TP. Key reaction components affect the kinetics and performance robustness of cell-free protein synthesis reactions. Computational and Structural Biotechnology Journal 2022, 20, 218-229.
• Collins A, Lendrem D, Wason J, Tarn J, Howard-Tripp N, Bodewes I, Versnel MA, Gottenberg J-E, Seror R, Mariette X, Ng W-F. Revisiting the JOQUER trial: stratification of primary Sjögren’s syndrome and the clinical and interferon response to hydroxychloroquine. Rheumatology International 2021, 41, 1593-1600.
• Serrano-Blesa E, Porter A, Lendrem DW, Pitzalis C, Barton A, Treumann A, Isaacs JD. Robust optimization of SWATH-MS workflow for human blood serum proteome analysis using a quality by design approach. Clinical Proteomics 2021, 18(1), 20.
• Hanrath AT, Schim van der Loeff I, Lendrem DW, Baker KF, Price DA, McDowall P, McDowall K, Cook S, Towns P, Schwab U, Evans A, Dixon J, Collins J, Burton-Fanning S, Saunders D, Harwood J, Samuel J, Schmid ML, Pareja-Cebrian L, Hunter E, Murphy E, Taha Y, Payne BAI, Duncan CJA. SARS-CoV-2 Testing of 11,884 Healthcare Workers at an Acute NHS Hospital Trust in England: A Retrospective Analysis. Frontiers in Medicine 2021, 8, 636160.
• Ellison C, Hackett K, Lendrem DW, Abley C. Exploring medicines reconciliation in the emergency assessment unit: staff perceptions and actual waiting times. Emergency Nurse 2020, 28(3), 1-10.
• Hunter E, Price DA, Murphy E, Schim van der Loeff I, Baker KF, Lendrem D, Lendrem C, Schmid ML, Pareja-Cebrian L, Welch A, Payne BAI, Duncan CJA. First experience of COVID-19 screening of health-care workers in England. The Lancet 2020, 395(10234), e77-e78.
• Tarn JR, Lendrem DW, Isaacs JD. In search of pathobiological endotypes: a systems approach to early rheumatoid arthritis. Expert Review of Clinical Immunology 2020, 16(6), 621-630.
• Baker KF, Thompson B, Lendrem DW, Scadeng A, Pratt AG, Isaacs JD. Lack of association between clinical and ultrasound measures of disease activity in rheumatoid arthritis remission. Therapeutic Advances in Musculoskeletal Disease 2020, 12.
• McMeekin P, Lendrem DW, Lendrem BC, Pratt AG, Peck R, Isaacs JD, Jones D. Schrödinger's pipeline and the outsourcing of pharmaceutical innovation. Drug Discovery Today 2020, 25(3), 480-484.
• Traianos EY, Locke J, Lendrem D, Bowman S, Hargreaves B, Macrae V, Tarn JR, Ng W-F. Serum CXCL₁₃ levels are associated with lymphoma risk and lymphoma occurrence in primary Sjögren’s syndrome. Rheumatology International 2020, 40, 541-548.
• Lendrem BC, Lendrem DW, Pratt AG, Naamane N, McMeekin P, Ng W-F, Allen AJ, Power M, Isaacs JD. Between a ROC and a hard place: Teaching prevalence plots to understand real world biomarker performance in the clinic. Pharmaceutical Statistics 2019, 18(6), 632-635.
• Fellermann H, Shirt-Ediss B, Kozyra J, Linsley M, Lendrem D, Isaacs J, Howard TP. Design of experiments and the virtual PCR simulator: An online game for pharmaceutical scientists and biotechnologists. Pharmaceutical Statistics 2019, 18(4), 402-406.
• Anderson AE, Maney NJ, Nair N, Lendrem DW, Skelton AJ, Diboll J, Brown PM, Smith GR, Carmody RJ, Barton A, Isaacs JD, Pratt AG. Expression of STAT3-regulated genes in circulating CD4+ T cells discriminates rheumatoid arthritis independently of clinical parameters in early arthritis. Rheumatology 2019, 58(7), 1250-1258.
• Davies K, Mirza K, Tarn J, Howard-Tripp N, Bowman SJ, Lendrem D, UK Primary Sjögren’s Syndrome Registry, Ng W-F. Fatigue in primary Sjögren’s syndrome (pSS) is associated with lower levels of proinflammatory cytokines: a validation study. Rheumatology International 2019, 39, 1867-1873.
• Miyamoto SM, Lendrem DW, Ng WF, Hackett KL, Valim VL. Managing fatigue in patients with primary Sjögren’s syndrome: challenges and solutions. Open Access Rheumatology: Research and Reviews 2019, 11, 77-88.
• Miyamoto S, Lendrem DW, Ng W-F, Hackett K, Valim V. Managing fatigue in patients with primary Sjögren's syndrome. Open Access Rheumatology: Research and Reviews 2019, 11, 77-88.
• Hackett KL, Davies K, Tarn J, Bragg R, Hargreaves B, Miyamoto S, McMeekin P, Mitchell S, Bowman S, Price EJ, Pease C, Emery P, Andrews J, Lanyon P, Hunter J, Gupta M, Bombardieri M, Sutcliffe N, Pitzalis C, McLaren J, Cooper A, Regan M, Giles I, Isenberg D, Vadivelu S, Coady D, Dasgupta B, McHugh N, Young-Min S, Moots R, Gendi N, Akil M, Griffiths B, Lendrem DW, Ng W-F. Pain and depression are associated with both physical and mental fatigue independently of comorbidities and medications in primary Sjögren's syndrome. RMD Open 2019, 5(1), e000885.
• Baker KF, Skelton AJ, Lendrem DW, Scadeng A, Thompson B, Pratt AG, Isaacs JD. Predicting drug-free remission in rheumatoid arthritis: A prospective interventional cohort study. Journal of Autoimmunity 2019, 105, 102298.
• Iqbal K, Lendrem DW, Hargreaves B, Isaacs JD, Thompson B, Pratt AG. Routine musculoskeletal ultrasound findings impact diagnostic decisions maximally in autoantibody-seronegative early arthritis patients. Rheumatology 2019, 58(7), 1268–1273.
• Miyamoto ST, Valim V, Carletti L, Ng W-F, Perez AJ, Lendrem DW, Trennel M, Giovelli RA, Dias LH, Serrano EV, Subtil AM, Abreu VC, Natour J. Supervised walking improves cardiorespiratory fitness, exercise tolerance, and fatigue in women with primary Sjögren’s syndrome: a randomized-controlled trial. Rheumatology International 2019, 39(2), 227-238.
• Tarn JR, Howard-Tripp N, Lendrem DW, Mariette X, Saraux A, Devauchelle-Pensec V, Seror R, Skelton AJ, James K, McMeekin P, Al-Ali S, Hackett KL, Lendrem BC, Hargreaves B, Casement J, Mitchell S, Bowman SJ, Price E, Pease CT, Emery P, Lanyon P, Hunter J, Gupta M, Bombardieri M, Sutcliffe N, Pitzalis C, McLaren J, Cooper A, Regan M, Giles I, Isenberg D, Saravanan V, Coady D, Dasgupta B, McHugh N, Young-Min S, Moots R, Gendi N, Akil M, Griffiths B, Johnsen SJA, Norheim KB, Omdal R, Stocken D, Everett C, Fernandez C, Isaacs JD, Gottenberg J-E, Ng WF, French ASSESS cohort, UK Primary Sjogren's Syndrome Registry. Symptom-based stratification of patients with primary Sjögren’s syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials. Lancet Rheumatology 2019, 1(2), e85-e94.
• Thalayasingam N, Nair N, Skelton AJ, Massey J, Anderson AE, Clark AD, Diboll J, Lendrem DW, Reynard LN, Cordell HJ, Eyre S, Isaacs JD, Barton A, Pratt AG. CD4+ and B lymphocyte expression quantitative traits at rheumatoid arthritis risk loci in untreated early arthritis: implications for causal gene identification. Arthritis and Rheumatology 2018, 70(3), 361-370.
• Dumusc A, Ng W-F, James K, Griffiths B, Price E, Pease CT, Emery P, Lanyon P, Jones A, Bombardieri M, Sutcliffe N, Pitzalis C, Gupta M, McLaren J, Cooper A, Giles I, Isenberg D, Saravanan V, Coady D, Dasgupta B, McHugh N, Young-Min S, Moots RJ, Gendi N, Akil M, Barone F, Fisher BA, Rauz S, Richards A, Bowman SJ, Frankland H, Mediana A, Chadravarty K, Lamabadusuriya S, Adeniba R, Hamburger J, Higham J, Poveda-Galego A, Logan J, Mulherin D, Andrews J, McManus A, Booth A, Regan M, Dimitroulas T, Kadiki L, Kaur D, Kitas G, Lloyd M, Moore L, Gordon E, Lawson C, Hunter J, Stirton L, Ortiz G, Clunie G, Rose G, Cuckow S, Knight S, Symmons D, Jones B, Carr A, Edgar S, Carrozzo M, Figueiredo F, Foggo H, Gillespie C, Hindmarsh V, Lendrem D, Macleod I, Mitchell S, Tarn J, Muir A, White P, Pugmire S, Watkins M, Field A, Kaye S, Mewar D, Medcalf P, Tomlinson P, Whiteside D, Pauling J, James J, Olaitan N, McDermott J, Godia O, Kidd E, Palmer L, Katsande V, Long P, Chandra U, MacKay K, Fedele S, Ferenkeh-Koroma A, Marconnell H, Porter S, Brailsford S, Allcoat P. Comparison of ESSDAI and ClinESSDAI in potential optimisation of trial outcomes in primary Sjögren's syndrome: Examination of data from the UK Primary Sjögren's Syndrome Registry. Swiss Medical Weekly 2018, 148, w14588.
• Baker KF, Thompson B, Lendrem D, Pratt AG, Isaacs JD. Lack of association between clinical and ultrasound measures of disease activity in rheumatoid arthritis clinical remission: a cross-sectional analysis. In: Annual European Congress of Rheumatology (EULAR 2018). 2018, Amsterdam: BMJ Publishing Group.
• Baker KF, Skelton AJ, Lendrem DW, Thompson B, Pratt AG, Isaacs JD. Predictors of drug-free remission in rheumatoid arthritis: results from the prospective Biomarkers of Remission in Rheumatoid Arthritis (BioRRA) Study. In: Annual European Congress of Rheumatology (EULAR 2018). 2018, Amsterdam: BMJ Publishing Group.
• Bodewes ILA, Al-Ali S, vanHelden-Seeuwsen CG, Maria NI, Tarn JR, Lendrem DW, Schreurs MWJ, Steenwijk EC, vanDaele PLA, Both T, Bowman SJ, Griffiths B, Ng WF, Versnel MA. Systemic interferon type I and type II signatures in primary Sjögren’s syndrome reveal differences in biological disease activity. Rheumatology 2018, 57(5), 921-930.
• Cope AP, Barnes MR, Belson A, Binks M, Brockbank S, Bonachela-Capdevila F, Carini C, Fisher BA, Goodyear CS, Emery P, Ehrenstein MR, Gozzard N, Harris R, Hollis S, Keidel S, Levesque M, Lindholm C, McDermott MF, McInnes IB, Mela CM, Parker G, Read S, Pedersen AW, Ponchel F, Porter D, Rao R, Rowe A, Schulze-Knappe P, Sleeman MA, Symmons D, Taylor PC, Tom B, Tsuji W, Verbeeck D, Isaacs JD, Anderson A, Stocks P, Lendrem D, Tarn J, Smith G, Casement J, Diboll J, Harry R, Simpson G, Toward R, Noble H, Parke A, Wu W, Clarke F, Scott D, Scott IC, Galloway J, Lempp H, Ibrahim F, Schwank S, Molyneux G, Lazarov T, Geissmann F, Donnelly I, Gilmour A, TulunayVirlan A, El-Jawhari J, Parmer R, Buch M, Buckley C, Young S, Jones P, Raza K, Filer A, Pitzalis C, Thorborn G, Fossati-Jimack L, Kelly S, Humby F, Novak T, Rana S, Goldmann K, Lewis M, Watson D, Jia Z, Altobelli G, John C, Martins S, Nguyen D, Ali H, Worthington J, Bruce I, Sergeant J, Verstappen S, D'Costa N, Stirling F, Hughes-Morley A, Farewell V, Zhong Y, Cuff C, Long A, Liu Z, Lipsky S, Harvey B, MacOritto M, Hong F, Kaymakcalan S, Sabin T, Ward N, Talbot S, Padhi D, Finch D, Herath A, Jenkins M, Ho M, Marshall C, Page M, Edwards H, Cuza A, Loza M, Curran M, Baker D, Vranic I, Mela CT, Wright S, Rowell L, Vernon E, Joseph N, Payne N, Ludbrook V, Hicks K, Tipney H, Ellis J, Hasan S, Didierlaurent A, Burny W, Haynes A, Larminie C, Dastros-Pitel D, Kola B, Jelinksy S, Hodge M, MacIejewski M, Ziemek D, Zucht H-D, Budde P. The RA-MAP Consortium: a working model for academia-industry collaboration. Nature Reviews Rheumatology 2018, 14(1), 53-60.
• Williams V, Syla D, Sweenie A, Lendrem D, Newton JL, Hackett KL. A scoping exercise to gauge the incidence of early post-stroke fatigue for patients at Newcastle community stroke services. International Journal of Therapy and Rehabilitation 2017, 24(2), 52.
• Cooles FAH, Anderson AE, Lendrem DW, Norris J, Pratt AG, Hilkens CMU, Isaacs JD. The interferon gene signature is increased in patients with early treatment-naive rheumatoid arthritis and predicts a poorer response to initial therapy. Journal of Allergy and Clinical Immunology 2017, 141(1), 445-448.e4.
• Howard-Tripp N, Tarn J, Gillespie C, Lendrem D, Griffiths B, Bowman S, Ng WF, United Kingdom Primary Sjögren's Syndrome Registry. A Cytokine-Mediated Biological Basis for Fatigue in Primary Sjögren’s Syndrome. In: Rheumatology 2016. 2016, Glasgow: Oxford University Press.
• Pratt AG, Lendrem D, Hargreaves B, Aslam O, Galloway JB, Isaacs JD. Components of treatment delay in rheumatoid arthritis differ according to autoantibody status: validation of a single-centre observation using national audit data. Rheumatology 2016, 55(10), 1843-1848.
• Hanson H, Isaacs JD, Kay LJ, Lendrem DW, O'Brien N, Pratt AG, Rapley T. Experiences of staff and patients in relation to clinical research recruitment and involvement: a qualitative study. In: Rheumatology. 2016, Glasgow: Oxford University Press.
• Tripp NH, Tarn J, Natasari A, Gillespie C, Mitchell S, Hackett KL, Bowman SJ, Price E, Pease CT, Emery P, Lanyon P, Hunter J, Gupta M, Bombardieri M, Sutcliffe N, Pitzalis C, McLaren J, Cooper A, Regan M, Giles I, Isenberg DA, Saravanan V, Coady D, Dasgupta B, McHugh N, Young-Min S, Moots R, Gendi N, Akil M, Griffiths B, Lendrem DW, Ng W-F. Fatigue in primary Sjögren's syndrome is associated with lower levels of proinflammatory cytokines. RMD Open 2016, 2, e000282.
• Pratt AG, Massey J, Anderson AE, Nair N, Diboll J, Skelton A, Lendrem DW, Reynard LN, Cordell HJ, Eyre S, Barton A, Isaacs JD. Identification of novel expression quantitative trait loci in CD4+ T cells of untreated early arthritis patients. In: 36th European Workshop for Rheumatology Research. 2016, York: BMJ Group.
• Hackett KL, Forder R, Lendrem DW, Hargreaves B, Strassheim V, Gotts Z, Deary V, Ng W-F, Newton JL. Objective Improvement in Fatigue Scores for Primary Sjögren’s Patients Receiving a Tailored Multidisciplinary Fatigue Intervention in a Generic Fatigue Clinic. In: ACR/ARHP Annual Meeting. 2016, Washington, DC: John Wiley & Sons, Inc.
• Lendrem DW, Lendrem BC, Linsley M, Rowland-Jones R, D'Agostino F, Owen MR, Isaacs JD. Teaching Examples for the Design of Experiments: Geographical Sensitivity and the Self-Fulfilling Prophecy. Pharmaceutical Statistics 2016, 15(1), 90-92.
• Baker KF, Thompson B, Lendrem DW, Pratt AG, Isaacs JD. Ultrasound measures of synovitis are independent of clinical parameters in the setting of rheumatoid arthritis remission: a cross-sectional analysis. In: 2016 Annual European Congress of Rheumatology. 2016, London, UK: BMJ Publishing Group.
• Hackett K, Lendrem DW, Rapley T, Deane K, Deary V, Bowman S, Newton J, Ng WF, United Kingdom Primary Sjogren's S. "Doing Every-Day Life" with Primary Sjogren's Syndrome: Factors Predicting Difficulties Performing Daily Activities and Taking on Life Roles. In: 2015 ACR/ARHP Annual Meeting. 2015, San Francisco, California: John Wiley & Sons.
• James K, Al-Ali S, Tarn J, Cockell SJ, Gillespie CS, Hindmarsh V, Locke J, Mitchell S, Lendrem D, Bowman S, Price E, Pease CT, Emery P, Lanyon P, Hunter JA, Gupta M, Bombardieri M, Sutcliffe N, Pitzalis C, McLaren J, Cooper A, Regan M, Giles I, Isenberg D, Saravanan V, Coady D, Dasgupta B, McHugh N, Young-Min S, Moots R, Gendi N, Akil M, Griffiths B, The UK Primary Sjögren’s Syndrome registry, Wipat A, Newton J, Jones DE, Isaacs J, Hallinan J, Ng W-F. A Transcriptional Signature of Fatigue Derived from Patients with Primary Sjögren’s Syndrome. PLoS ONE 2015, 10(12), e0143970.
• Lambson RL, Hargreaves B, Lendrem DW, Hindmarsh V, Humphrey C, Mitchell S, Griffiths B, Bowman S, Ng WF, UKPSS Registry. Assignable Causes for Fatigue in Primary Sjögren’s Syndrome: Data from the UK Primary Sjögren’s Syndrome Registry. In: 2015 ACR/ARHP Annual Meeting Abstract Supplement. 2015, San Francisco, California: Wiley-Blackwell.
• Hackett K, Lendrem D, Frith J, Rapley T, Deary V, Deane K, Bowman S, Newton J, Ng W-F. Cognitive Impairment in Primary Sjögren’s Syndrome. In: Rheumatology 2015. 2015, Manchester, UK: S. Karger AG.
• Hackett K, Lendrem D, Frith J, Rapley T, Deary V, Deane K, Bowman S, Newton J, Ng WF. Cognitive Symptoms are Common in Primary Sjogren's Syndrome and are Associated with Anxiety. In: 13th International Symposium on Sjögren's Syndrome. 2015, Bergen, Norway: Wiley-Blackwell Publishing Ltd.
• Hackett K, Lendrem D, Frith J, Rapley T, Deary V, Deane K, Bowman S, Newton J, Ng W-F. Cognitive symptoms are common in primary Sjögren's syndrome and are associated with anxiety. In: 13th International Symposium on Sjögren's Syndrome. 2015, Bergen, Norway: Wiley-Blackwell Publishing Ltd.
• Pratt AG, Hargreaves B, Lendrem DW, Aslam O, Isaacs JD. Components of treatment delay in rheumatoid arthritis differ according to autoantibody status. In: 2015 ACR/ARHP Annual Meeting. 2015, San Francisco, CA, USA: John Wiley & Sons, Inc.
• Lendrem D, Mitchell S, McMeekin P, Gompels L, Hackett K, Bowman S, Price E, Pease CT, Emery P, Andrews J, Lanyon P, Hunter J, Gupta M, Bombardieri M, Sutcliffe N, Pitzalis C, McLaren J, Cooper A, Regan M, Giles I, Isenberg D, Vadivelu S, Coady D, Dasgupta B, McHugh N, Young-Min S, Moots R, Gendi N, Akil M, Griffiths B, Ng W-F. Do the EULAR Sjögren’s syndrome outcome measures correlate with health status in primary Sjögren’s syndrome?. Rheumatology 2015, 54(4), 655-659.
• Zheng J, vandeVeerdonk FL, Crossland KL, Smeekens SP, Chan CM, AlShehri T, Abinun M, Gennery AR, Mann J, Lendrem DW, Netea MG, Rowan AD, Lilic D. Gain-of-function STAT1 mutations impair STAT3 activity in patients with Chronic Mucocutaneous Candidiasis (CMC). European Journal of Immunology 2015, 45(10), 2834-2846.
• Lendrem DW, Lendrem BC, Woods D, Rowland-Jones R, Burke M, Chatfield M, Isaacs JD, Owen MR. Lost in Space: Design of Experiments and Scientific Exploration in a Hogarth Universe. Drug Discovery Today 2015, 20(11), 1365-1371.
• Tarn J, Lendrem D, Gillespie C, Al-Ali S, Griffiths B, Bowman S, Ng WF, Uk Primary Sjogren's Syndrome Regi. Patient Sub-Phenotyping in Primary Sjogren's Syndrome. In: 13th International Symposium on Sjögren's Syndrome. 2015, Bergen, Norway: Wiley-Blackwell Publishing Ltd.
• Lendrem DW. Pharmaceutical R&D Productivity: Be Careful What You Wish For. Chemistry World 2015, 12(4), 40.
• Lendrem DW, Lendrem BC, Peck RW, Senn SJ, Day S, Isaacs JD. Progression-seeking bias and rational optimism in research and development. Nature Reviews Drug Discovery 2015, 14, 219-221.
• Cooles FAH, Pratt AG, Lendrem DW, Ng WF, Aspray TJ, Isaacs JD. Retrospective analysis of the role of serum vitamin D in early rheumatic disease. Rheumatology 2015, 54(2), 374-375.
• Pratt AG, Anderson AE, Lendrem DW, Skelton A, Massey J, Nair N, Diboll J, Hargreaves B, Brown PM, Barton A, Isaacs JD. STAT3-regulated gene expression in circulating CD4+ T cells discriminates RA patients independently of clinical parameters in early arthritis: a validation study. In: 2015 ACR/ARHP Annual Meeting. 2015, San Francisco, CA.
• Pratt AG, Anderson AE, Nair N, Massey J, Diboll J, Skelton A, Hargreaves B, Routledge C, Lendrem D, Brown P, Barton A, Isaacs JD. The Importance of IL-6-STAT₃ Mediated Activation of Circulating CD4⁺ T Cells in the Pathogenesis of Early Seronegative Rheumatoid Arthritis: A Validation Study. In: Rheumatology 2015. 2015, Manchester, UK: Oxford University Press.
• Peck RW, Lendrem DW, Grant I, Lendrem BC, Isaacs JD. Why is it hard to terminate failing projects in pharmaceutical R&D?. Nature Reviews Drug Discovery 2015, 14, 1-2.
• Lendrem BD, Lendrem DW, Gray A, Isaacs JD. Christmas 2014: Going to Extremes. The Darwin Awards: sex differences in idiotic behaviour. BMJ 2014, 349, g7094.
• Hackett KL, Newton JL, Deane KHO, Rapley T, Deary V, Kolehmainen N, Lendrem DW, Ng W-F. Developing a service user informed intervention to improve participation and ability to perform daily activities in primary Sjӧgren’s syndrome: a mixed methods study protocol. BMJ Open 2014, 4(8), e006264.
• Zheng J, de Veerdonk FV, Crossland K, Smeekens SP, Abinun M, Gennery AR, Mann J, Lendrem D, Netea MG, Rowan AD, Lilic D. Gain-of-function stat1 mutation impairs stat3 function predisposing to chronic mucocutaneous candidiasis. In: 100th J Project Meeting. 2014, Antalya, TURKEY: Springer.
• Lendrem D, Mitchell S, McMeekin P, Bowman S, Price E, Pease C, Emery P, Andrews J, Lanyon P, Hunter J, Gupta M, Bombardieri M, Sutcliffe N, Pitzalis C, McLaren J, Cooper A, Regan M, Giles I, Isenberg D, Vadivelu S, Coady D, Dasgupta B, McHugh N, Young-Min S, Moots S, Gendi N, Akil M, Griffiths B, Ng W-F. Health-related utility values of patients with primary Sjögren's syndrome and its predictors. Annals of Rheumatic Diseases 2014, 73(7), 1362-1368.
• Lendrem DW, Senn SJ, Lendrem BC, Isaacs JD. R&D Productivity Rides Again?. Pharmaceutical Statistics 2014.
• Cooles FAH, Pratt AG, Lendrem DW, Ng W-F, Aspray TJ, Isaacs JD. Retrospective analysis of the role of serum vitamin D in early rheumatic disease. Rheumatology 2014.
• Lendrem B, Lendrem DW, Gray A, Isaacs JD. The Darwin Awards: Gender Differences in Idiotic Behaviour. British Medical Journal 2014, 349, g7094.
• Lendrem D, Lendrem BC. The Development Speed Paradox: Can increasing development speed reduce R&D productivity?. Drug Discovery Today 2014, 19(3), 209-214.
• Lendrem DW. The Norm Chronicles: stories and numbers about danger by Michael Blastland and David Spiegelhalter [Book review]. Statistics in Medicine 2014, 33(4), 719-720.
• James K, Lendrem D, Mitchell S, Hindmarsh V, Bowman S, Price EJ, Pease CT, Emery P, Lanyon P, Hunter J, Gupta M, Bombardieri M, Sutcliffe N, Pitzalis C, McLaren J, Cooper A, Regan M, Giles IP, Isenberg DA, Vadivelu S, Coady D, Dasgupta B, McHugh N, Griffiths B, Ng WF. The UK Primary Sjögren’s Syndrome Registry (UKPSSR): A Valuable Resource for Future Sjögren’s Syndrom Research. In: Rheumatology 2014. 2014, Liverpool, UK: Oxford University Press.
• Collins K, Balasubramaniam K, Viswanathan G, Natasari A, Tarn J, Lendrem D, Mitchell S, Zaman A, Ng W-F. Assessment of blood clot formation and platelet receptor function ex vivo in patients with primary Sjögren’s syndrome. BMJ Open 2013, 3(5), e002739.
• Nordmark G, Wang C, Vasaitis L, Eriksson P, Theander E, Kvarnström M, Forsblad-d'Elia H, Jazebi H, Sjöwall C, Reksten TR, Brun JG, Jonsson MV, Johnsen SJ, Wahren-Herlenius M, Omdal R, Jonsson R, Bowman S, Ng WF, Eloranta ML, Syvänen AC, UK Primary Sjögren's Syndrome Registry, Carr A, Corbett I, Carrozzo M, Lendrem D, Macleod I, Mawson P, Stocks P. Association of genes in the NF-κB pathway with antibody-positive primary Sjögren's syndrome. Scandinavian Journal of Immunology 2013, 78(5), 447-454.
• Lendrem DW. Bad pharma: how drug companies mislead doctors and harm patients by Ben Goldacre. Pharmaceutical Statistics 2013, 12(3), 186-187.
• Natasari AS, Tarn JR, Fischer R, Lendrem DW, Ng W-F. Exploring the biological basis of fatigue using primary Sjögren's syndrome as a disease model. BMC Musculoskeletal Disorders 2013, 14(S1), A1.
• Lendrem DW, Lendrem BC. Torching the Haystack: Modelling fast-fail strategies in drug development. Drug Discovery Today 2013, 18(7-8), 331-336.
• Newton JL, Frith J, Powell D, Hackett K, Wilton K, Bowman S, Price E, Pease C, Andrews J, Emery P, Hunter J, Gupta M, Vadivelu S, Giles I, Isenberg D, Lanyon P, Jones A, Regan M, Cooper A, Moots R, Sutcliffe N, Bombardieri M, Pitzalis C, McLaren J, Young-Min S, Dasgupta B, Griffiths B, Lendrem D, Mitchell S, Ng WF. Autonomic symptoms are common and are associated with overall symptom burden and disease activity in primary Sjögren's syndrome. Annals of the Rheumatic Diseases 2012, 71(12), 1973-1979.
• Lendrem D, Mitchell S, Bowman S, Price E, Pease CT, Emery P, Andrews J, Bombardieri M, Sutcliffe N, Pitzalis C, Lanyon P, Hunter J, Gupta M, McLaren J, Regan M, Cooper A, Giles I, Isenberg D, Griffiths B, Foggo H, Edgar S, Vadivelu S, Coady D, McHugh N, Ng WF. Evaluating health status of 620 patients with primary sjögren’s syndrome using EQ-5D. In: Annual Meeting of the British Society for Rheumatology. 2012, Glasgow, UK: Oxford University Press.
• Ng WF, Lendrem D, Mitchell S, Bowman S, Price E, Pease C, Emery P, Andrews J, Bombardieri M, Sutcliffe N, Pitzalis C, Lanyon P, Hunter J, Gupta M, McLaren J, Regan M, Cooper A, Giles I, Isenberg D, Vadivelu S, Coady D, Griffiths B, United Kingdom Primary Sjogrens Syndrome. Evaluating health status of 620 patients with primary Sjögren's syndrome using EQ-5D. In: Annual European Congress of Rheumatology EULAR. 2012, Berlin, Germany: BMJ Publishing Group.
• Ng WF, Mitchell S, Lendrem D, Bowman S, Price E, Pease C, Emery P, Andrews J, Bombardieri M, Sutcliffe N, Pitzalis C, Lanyon P, Hunter J, Gupta M, McLaren J, Regan M, Cooper A, Giles I, Isenberg D, Vadivelu S, Coady D, Griffiths B, United Kingdom Primary Sjogren's. How good are the EULAR Sj ögren's syndrome disease activity index (ESSDAI), and EULAR Sj ögren's syndrome patients reported index (ESSPRI) in predicting health status in primary Sj ögren's syndrome? Normal 0 false false false EN-GB X-NONE X-NONE Normal 0 false false false EN-GB X-NONE X-NONE Normal 0 false false false EN-GB X-NONE X-NONE. In: Annual European Congress of Rheumatology EULAR. 2012, Berlin, Germany: BMJ Publishing Group.
• Lendrem D, Mitchell S, Bowman S, Price E, Pease CT, Emery P, Andrews J, Bombardieri M, Sutcliffe N, Pitzalis C, Lanyon P, Hunter J, Gupta M, McLaren J, Regan M, Cooper A, Giles I, Isenberg D, Vadivelu S, Coady D, McHugh N, Griffiths B, Foggo H, Edgar S, Ng WF. How good are the eular sjögren’s syndrome disease activity index, and eular sjögren’s syndrome patients reported index in predicting health status in primary sjögren’s syndrome?. In: Annual Meeting of the British Society for Rheumatology. 2012, Glasgow, UK: Oxford University Press.
• Hackett KL, Newton JL, Frith J, Elliott C, Lendrem D, Foggo H, Edgar S, Mitchell S, Ng F. Impaired functional status in primary Sjogren's syndrome. Arthritis Care & Research 2012, 64(11), 1760-1764.
• Tarn J, Mitchell S, Bowman S, Price E, Pease C, Sutcliffe N, Emery P, Andrews J, Bombardieri M, Pitzalis C, Lanyon P, Hunter J, Gupta M, Regan M, Cooper A, Giles I, Isenberg D, Young D, Lendrem D, McLaren J, Downie C, Foggo H, Stocks P, Edgar S, Ng WF, UK Primary Sjogrens Syndrome. Serum cytokine and chemokine profiling in primary Sj ögren's syndrome Normal 0 false false false EN-GB X-NONE X-NONE. In: Annual European Congress of Rheumatology EULAR. 2012, Berlin, Germany: BMJ Publishing Group.
• Tarn J, Natasari A, Mitchell S, Lendrem D, Downie C, Foggo H, Young D, Ng W, Bowman S. Soluble molecule profiling and network analysis of primary Sjogren's syndrome patient serum. In: European Congress of Immunology. 2012, Glasgow, UK: Wiley-Blackwell Publishing Ltd.
• Vila J, Mitchell S, Bowman S, Price E, Pease CT, Emery P, Andrews J, Bombardieri M, Sutcliffe N, Pitzalis C, Lanyon P, Hunter J, Gupta M, McLaren J, Regan M, Cooper A, Giles I, Isenberg D, Vadivelu S, Coady D, Griffiths B, Lendrem D, Foggo H, Tarn J, Ng WF. The clinical relevance of anti-RO52 and anti-RO60 in patients in the united kingdom primary sjögren’s syndrome registry (UKPSSR). In: Annual Meeting of the British Society for Rheumatology. 2012, Glasgow, UK: Oxford University Press.
• Lendrem DW. Statistical support to non-clinical. Pharmaceutical Statistics 2002, 1(2), 71-73.
• Lendrem D, Owen M, Godbert S. DOE (Design of Experiments) in Development Chemistry: Potential Obstacles. Organic Process Research & Development 2001, 5(3), 324-327.
• Lendrem DW. Enhancing process development capabilities. Pharmaceutical Technology Europe 2000, 12, 46-49.
• McGurk JG, Lendrem DW, Potter CJ. Use of Statistical Experimental Design in Laboratory Scale Formulation Optimisation and Progression to Plant Scale. J. Pharmaceutical Technology 1998, 17, 2341-2358.
• Graham MA, Senan S, Hernani R, Eckhardt N, Lendrem D, Hincks J, Greenslade D, Rampling R, Kaye SB, Roemeling R, Workman P. Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trial. Cancer Chemother Pharmacol 1997, 40, 1-10.
• Woolfrey SG, Hegbrant J, Thysell H, Fox PA, Lendrem DW, Lockwood GF, Lasher K, Rogers J, Greenslade D. Dose regimen adjustment for milrinone in congestive heart failure patients with moderate and severe renal failure. Journal of pharmacy and pharmacology 1995, 47, 651-655.
• Lendrem DW. More haste, less development speed. Scrip Magazine 1995, (May), 22-23.
• Robertson A, Wiles A, Alexander J, Clark P, Godley M, Lendrem D. Standard Operating Procedures. Drug Information Journal 1995, 29(2), 497-502.
• Hodsdon AC, Lendrem DW, Mitchell JR, Davies MC, Melia CD. The influence of wet granulation on the performance of xanthan gum as a hydrophilic matrix sustained release carrier. Journal of Controlled Release 1994, 21, 726-727.
• McGurk JG, Storey R, Lendrem DW. Computer aided process optimization: tablet film coating. Journal of Pharmacy and Pharmacology 1989, 41, 120.
• Jones SP, Sandhu G, Lendrem DW. Enteric coating: formulation optimization and sampling technique. Journal of Pharmacy and Pharmacology 1989, 41(S1), 122.
• Lendrem DW. Kinship, pheromones and reproduction. In: Passera, L; Lachaud, J-P, ed. The Individual and Society. Toulouse: IEC, 1986, pp.67-71.
• Lendrem DW. Kinship affects puberty acceleration in mice (Mus musculus). Behavioural Ecology & Sociobiology 1985, 17, 397-399.
• LENDREM DW. KINSHIP AFFECTS PUBERTY ACCELERATION IN MICE (MUS-MUSCULUS). BEHAVIORAL ECOLOGY AND SOCIOBIOLOGY 1985, 17(4), 397-399.
• LENDREM D. STATISTICAL PARADOX. NEW SCIENTIST 1985, 106(1457), 47-47.
• LENDREM D. STATISTICAL TESTING IN DERMATOGLYPHIC STUDIES. HUMAN HEREDITY 1985, 35(4), 271-272.
• Lendrem DW. Should John McEnroe grunt?. New Scientist 1983, 99(1367), 188-189.